Signifor LAR®

Active substance Pasireotide
Holder N.V. Novartis Pharma S.A
Status Closed
Indication Patients with acromegaly who are inadequately controlled with 1st generation somatostatin analogues
Public documents Approbation
Information for the patient
Informed consent
Last update 06/05/2020
Last updated on 13/09/2024